As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here


he pharmaceutical industry may be flush with cash and generating some genuine breakthrough treatments, but drug makers will remain embattled in the coming year.

Pharma’s perpetual race for profits and reliance on the U.S. as its biggest customer are certain to cause tensions as Americans struggle with pocketbook anxiety over high drug prices. Similarly, various moves to fend off competition will continue to generate scrutiny. And you can be certain industry hiring and investment will be closely tracked now that drug makers are getting a windfall from the new tax bill.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Observer079 Cancel reply

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.